clients, partners and patients to develop new treatments for NASH, diabetes and obesity.
Clinical Development and Regulatory Strategy + State-of-the-Art Clinical Facility + Full Scope CRO Services + Global Scientific Network
ProSciento Expands Executive Team, Appoints Brian Mooney Chief Operating Officer Read More »
ProSciento and Tidepool Collaborate to Integrate Diabetes Device Data Aggregation Platform into Clinical Trials Read More »
View Our Presentation
Pathophysiology of Cardiovascular Disease in Diabetes Mellitus Read More »
Single Dose Euglycemic Clamp Studies Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between MK-1293 Insulin Glargine and Originator Insulin Glargine (Lantus) in Type 1 Diabetes and Healthy Subjects Read More »
FDA approves Ozempic to improve glycemic control in adults with T2D Read More »